SCA
CRSP icon

Snowden Capital Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Snowden Capital Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,843
Closed -$202K – 1299
2025
Q4 		$202K Sell
3,843
-150
-4% -$8.98K 0.01% 1218
2025
Q3 		$259K Buy
+3,993
New +$229K 0.01% 1085
2025
Q2 		– Sell
-5,889
Closed -$200K – 1217
2025
Q1 		$200K Buy
+5,889
New +$250K 0.01% 1162
2024
Q4 		– Sell
-9,818
Closed -$461K – 1220
2024
Q3 		$461K Buy
9,818
+36
+0.4% +$1.83K 0.01% 811
2024
Q2 		$528K Buy
9,782
+237
+2% +$13.7K 0.02% 727
2024
Q1 		$651K Buy
9,545
+3,412
+56% +$244K 0.02% 646
2023
Q4 		$384K Buy
6,133
+668
+12% +$36.9K 0.01% 817
2023
Q3 		$248K Sell
5,465
-347
-6% -$17.9K 0.01% 924
2023
Q2 		$326K Hold
5,812
– – 0.01% 922
2023
Q1 		$263K Sell
5,812
-778
-12% -$37.8K 0.01% 988
2022
Q4 		$268K Sell
6,590
-25
-0.4% -$1.33K 0.01% 964
2022
Q3 		$432K Sell
6,615
-993
-13% -$72K 0.02% 708
2022
Q2 		$462K Sell
7,608
-854
-10% -$50.2K 0.02% 667
2022
Q1 		$531K Sell
8,462
-1,043
-11% -$65.5K 0.02% 614
2021
Q4 		$720K Sell
9,505
-4,179
-31% -$365K 0.04% 386
2021
Q3 		$1.53M Buy
13,684
+437
+3% +$54.9K 0.08% 299
2021
Q2 		$2.14M Sell
13,247
-5,468
-29% -$665K 0.11% 250
2021
Q1 		$2.28M Buy
18,715
+2,323
+14% +$351K 0.13% 218
2020
Q4 		$2.51M Buy
+16,392
New +$1.94M 0.17% 183

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Snowden Capital Advisors's CRSP Position: Q1 2026 in Review

Snowden Capital Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 3,843 shares — an estimated $202K sold.

Snowden Capital Advisors first reported a position in CRSP in Q4 2020 and held it in 19 quarters. The position peaked at $2.51M in Q4 2020. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Snowden Capital Advisors reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Snowden Capital Advisors sold 3,843 CRISPR Therapeutics shares in Q1 2026, an estimated $202K.
  • Snowden Capital Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 19 quarters.
  • Snowden Capital Advisors's CRISPR Therapeutics position peaked at $2.51M in Q4 2020.
  • 492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.